About 4,950 results

ALLMedicine™ Cutaneous Melanoma Center

Research & Reviews  1,787 results

Screening of Autophagy-Related Prognostic Genes in Metastatic Skin Melanoma.
Disease Markers; Chen CJ, Kajita H et. al.

Jan 25th, 2022 - Cutaneous melanoma refers to a common skin tumor that is dangerous to health with a great risk of metastasis. Previous researches reported that autophagy is associated with the progression of cutaneous melanoma. Nevertheless, the role played by ge...

Trends and projections in cutaneous melanoma death in the Netherlands from 1950 to 2045.
Medicine van Niekerk CC, Groenewoud HMM et. al.

Jan 21st, 2022 - Child sun protection has recently been linked to the future disappearance of fatal melanoma in adults in successive generations. In the Netherlands, however, mortality rates from melanoma have increased gradually from the 1950s, with some indicati...

Conjunctival Metastasis From Cutaneous Melanoma Demonstrating Complete Regression Follo...
JAMA Ophthalmology; DeSimone JD, Lally SE et. al.

Jan 21st, 2022 - Conjunctival Metastasis From Cutaneous Melanoma Demonstrating Complete Regression Following Checkpoint Inhibitor Therapy.|2022|DeSimone JD,Lally SE,Shields CL,|

A B-Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to...
Cancer Medicine; Yao K, Zhou E et. al.

Jan 20th, 2022 - B-Raf V600E mutations account for about half of all skin cutaneous melanoma cases, and patients with this mutation are sensitive to BRAF inhibitors. However, aberrations in other genes in the MAPK/ERK pathway may cascade a similar effect as B-Raf ...

Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in...
The British Journal of Dermatology; Wei X, Wu D et. al.

Jan 19th, 2022 - Ulceration is regarded as an adverse prognostic factor and used together with tumor thickness to subcategorize cutaneous melanoma patients. However, the prognostic impact of ulceration in acral melanoma (AM) is controversial. Assess the prognostic...

see more →

Guidelines  8 results

SEOM clinical guideline for the management of cutaneous melanoma (2020).
Clinical & Translational Oncology : Official Publication ... Majem M, Manzano JL et. al.

Mar 3rd, 2021 - Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of t...

Systemic Therapy for Melanoma: ASCO Guideline.
Journal of Clinical Oncology : Official Journal of the Am... Seth R, Messersmith H et. al.

Apr 2nd, 2020 - To provide guidance to clinicians regarding the use of systemic therapy for melanoma. ASCO convened an Expert Panel and conducted a systematic review of the literature. A systematic review, one meta-analysis, and 34 additional randomized trials we...

Guidelines of care for the management of primary cutaneous melanoma.
Journal of the American Academy of Dermatology; Swetter SM, Tsao H et. al.

Nov 6th, 2018 - The incidence of primary cutaneous melanoma continues to increase each year. Melanoma accounts for the majority of skin cancer-related deaths, but treatment is usually curative following early detection of disease. In this American Academy of Derm...

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immun...
Journal for Immunotherapy of Cancer; Sullivan RJ, Atkins MB et. al.

Jun 1st, 2018 - Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination regimens for patien...

New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distan...
Journal of the National Comprehensive Cancer Network : JN... Barker CA, Salama AK

May 23rd, 2018 - The NCCN Guidelines Panel for Melanoma debuted new guidelines for uveal melanoma at the NCCN 23rd Annual Conference. Although uveal melanoma and cutaneous melanoma share the same name, they do have different characteristics and treatments. The NCC...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  39 results

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

Jan 10th, 2022 - Nivolumab is approved by the FDA for the treatment of melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of head/neck, urothelial carcinoma, MSI-H...

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

Jan 3rd, 2022 - The main purpose of this study is to compare the efficacy, as measured by recurrence-free survival (RFS) by blinded independent central review (BICR), of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage ...

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Dec 21st, 2021 - The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma an...

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Dec 21st, 2021 - This is a Phase 1, open-label, multicenter, dose-escalation study of intratumoral injections of mRNA-2752 alone and in combination with intravenously administered immune checkpoint blockade therapy in participants with histologically confirmed adv...

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Dec 17th, 2021 - This study will determine whether there is a difference in disease-free survival rates for patients with primary cutaneous melanoma with Breslow thickness > 2mm or 1-2mm with ulceration (pT2b-pT4b, AJCC 8th edition), treated with either a 1cm exci...

see more →

News  145 results

Dr. Weber Discusses Unmet Needs in Ocular and Mucosal Melanoma

Dec 15th, 2021 - Jeffrey S. Weber, MD, PhD, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Grossman School of Medicine, deputy director, Perlmutter Cancer Center, codirector, Melanoma Research Program, NYU Langone Health, discusses u...

Practice-Changing and Reaffirming Data Set Up an Exciting Future in Melanoma

Nov 24th, 2021 - Positive data readouts from studies such as the phase 2/3 RELATIVITY-047 trial (NCT03470922) with relatlimab and nivolumab (Opdivo), and the phase 3 KEYNOTE-716 trial (NCT03553836) with pembrolizumab (Keytruda), cemented 2021 as a banner year for ...

Nemvaleukin Alfa Plus Pembrolizumab Gets Fast Track Status for Platinum-Resistant Ovarian Cancer

Oct 26th, 2021 - The FDA has granted a fast track designation to the interleukin-2 (IL-2) variant immunotherapy nemvaleukin alfa (nemvaleukin) in combination with pembrolizumab (Keytruda) for the treatment of patients with platinum-resistant ovarian cancer.1 The ...

Targeted Therapy Combinations Still Key in Metastatic Melanoma

Oct 6th, 2021 - Jeffrey S. Weber, MD, PhD Combinations of targeted therapies continue to advance toward full regulatory approval for patients with metastatic or unresected melanoma, given the substantial benefits seen with these agents. At this time, the FDA is ...

John Theurer Cancer Center Evaluating Personalized Cancer Vaccine in High-Risk Melanoma

Oct 6th, 2021 - Andrew L. Pecora, MD An ongoing clinical trial will assess whether the adjuvant combination of the personalized cancer vaccine mRNA-4157 and pembrolizumab (Keytruda) improves recurrence-free survival (RFS) compared with pembrolizumab alone in pat...

see more →